These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 29028981

  • 1. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.
    J Crohns Colitis; 2018 Jan 24; 12(2):145-156. PubMed ID: 29028981
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.
    Dubinsky MC, DiBonaventura M, Fan H, Bushmakin AG, Cappelleri JC, Maller E, Thorpe AJ, Salese L, Panés J.
    Inflamm Bowel Dis; 2021 Jun 15; 27(7):983-993. PubMed ID: 32794567
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
    Davies SC, Hussein IM, Nguyen TM, Parker CE, Khanna R, Jairath V.
    Cochrane Database Syst Rev; 2020 Jan 27; 1(1):CD012381. PubMed ID: 31984480
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
    Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG.
    Clin Gastroenterol Hepatol; 2020 Jan 27; 18(1):123-132.e3. PubMed ID: 31077827
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
    Dubinsky MC, Armuzzi A, Gecse KB, Ullman T, Bushmakin AG, DiBonaventura M, Cappelleri JC, Connelly SB, Woolcott JC, Salese L.
    Dig Dis; 2023 Jan 27; 41(4):604-614. PubMed ID: 36603566
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.
    Panés J, Vermeire S, Dubinsky MC, Loftus EV, Lawendy N, Wang W, Salese L, Su C, Modesto I, Guo X, Colombel JF.
    J Crohns Colitis; 2021 Nov 08; 15(11):1852-1863. PubMed ID: 33884415
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
    Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE.
    Clin Gastroenterol Hepatol; 2022 Mar 08; 20(3):591-601.e8. PubMed ID: 33684552
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, Lawendy N, Friedman GS, Quirk D, Su C, Reinisch W.
    Clin Gastroenterol Hepatol; 2022 Jan 08; 20(1):116-125.e5. PubMed ID: 33039585
    [Abstract] [Full Text] [Related]

  • 18. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
    Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A.
    Clin Pharmacol Drug Dev; 2021 Mar 08; 10(3):229-240. PubMed ID: 33513294
    [Abstract] [Full Text] [Related]

  • 19. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.
    Lee SD, Allegretti JR, Steinwurz F, Connelly SB, Lawendy N, Paulissen J, Gecse KB.
    BMC Gastroenterol; 2023 Feb 08; 23(1):34. PubMed ID: 36755231
    [Abstract] [Full Text] [Related]

  • 20. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.
    Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panés J, Rubin DT.
    Inflamm Bowel Dis; 2023 Sep 01; 29(9):1370-1379. PubMed ID: 36242764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.